BST-2/tetherin: Structural biology, viral antagonism, and immunobiology of a potent host antiviral factor

Molecular Immunology

Volumn 54, Issue 2, 2013, Pages 132-139

  Swiecki, Melissa ^a   Omattage, Natalie S ^a   Brett, Tom J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral state; Innate immunity; Interferon; Plasmacytoid dendritic cells; Tetherin; Virology

Indexed keywords

PEPTIDES AND PROTEINS; PROTEIN BST2; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; HUMAN; IMMUNOBIOLOGY; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VIRUS REPLICATION;

EID: 84871648210     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.11.008     Document Type: Review

References (89)

1. Andrew A.J., Miyagi E., Kao S., Strebel K. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009, 6:80.
2. Barrett B.S., Smith D.S., Li S.X., Guo K., Hasenkrug K.J., Santiago M.L. A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathogens 2012, 8:e1002596.
3. Bego M.G., Mercier J., Cohen E.A. Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. Journal of Virology 2012, 86:3513-3527.
4. Blasius A.L., Giurisato E., Cella M., Schreiber R.D., Shaw A.S., Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. Journal of Immunology 2006, 177:3260-3265.
5. Bruce E.A., Abbink T.E., Wise H.M., Rollason R., Galao R.P., Banting G., Neil S.J., Digard P. Release of filamentous and spherical influenza A virus is not restricted by tetherin. Journal of General Virology 2012, 93:963-969.
6. Cai D., Cao J., Li Z., Zheng X., Yao Y., Li W., Yuan Z. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 2009, 9:102.
7. Cao W., Bover L., Cho M., Wen X., Hanabuchi S., Bao M., Rosen D.B., Wang Y.H., Shaw J.L., Du Q., et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. Journal of Experimental Medicine 2009, 206:1603-1614.
8. Cisse B., Caton M.L., Lehner M., Maeda T., Scheu S., Locksley R., Holmberg D., Zweier C., den Hollander N.S., Kant S.G., et al. Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 2008, 135:37-48.
9. Cole G., Simonetti K., Ademi I., Sharpe S. Dimerization of the transmembrane domain of human tetherin in membrane mimetic environments. Biochemistry 2012, 51:5033-5040.
10. Cyster J.G., Ansel K.M., Reif K., Ekland E.H., Hyman P.L., Tang H.L., Luther S.A., Ngo V.N. Follicular stromal cells and lymphocyte homing to follicles. Immunological Reviews 2000, 176:181-193.
11. Dafa-Berger A., Kuzmina A., Fassler M., Yitzhak-Asraf H., Shemer-Avni Y., Taube R. Modulation of hepatitis C virus release by the interferon-induced protein BST-2/tetherin. Virology 2012, 428:98-111.
12. Douglas J.L., Viswanathan K., McCarroll M.N., Gustin J.K., Fruh K., Moses A.V. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. Journal of Virology 2009, 83:7931-7947.
13. Dube M., Bego M.G., Paquay C., Cohen E.A. Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 2010, 7:114.
14. Erikson E., Adam T., Schmidt S., Lehmann-Koch J., Over B., Goffinet C., Harter C., Bekeredjian-Ding I., Sertel S., Lasitschka F., et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:13688-13693.
15. Evans D.T., Serra-Moreno R., Singh R.K., Guatelli J.C. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends in Microbiology 2010, 18:388-396.
16. Fitzpatrick K., Skasko M., Deerinck T.J., Crum J., Ellisman M.H., Guatelli J. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathogens 2010, 6:e1000701.
17. Frost A., Unger V.M., De Camilli P. The BAR domain superfamily: membrane-molding macromolecules. Cell 2009, 137:191-196.
18. Galao R.P., Le Tortorec A., Pickering S., Kueck T., Neil S.J. Innate Sensing of HIV-1 Assembly by Tetherin Induces NFkappaB-Dependent Proinflammatory Responses. Cell Host & Microbe 2012, 12:633-644.
19. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nature Reviews Immunology 2008, 8:594-606.
20. Goffinet C., Allespach I., Homann S., Tervo H.M., Habermann A., Rupp D., Oberbremer L., Kern C., Tibroni N., Welsch S., et al. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host & Microbe 2009, 5:285-297.
21. Goto T., Kennel S.J., Abe M., Takishita M., Kosaka M., Solomon A., Saito S. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994, 84:1922-1930.
22. Gupta R.K., Hue S., Schaller T., Verschoor E., Pillay D., Towers G.J. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathogens 2009, 5:e1000443.
23. Habermann A., Krijnse-Locker J., Oberwinkler H., Eckhardt M., Homann S., Andrew A., Strebel K., Krausslich H.G. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. Journal of Virology 2010, 84:4646-4658.
24. Hammonds J., Ding L., Chu H., Geller K., Robbins A., Wang J.J., Yi H., Spearman P. The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release. Journal of Virology 2012, 86:2259-2272.
25. Hammonds J., Wang J.J., Yi H., Spearman P. Immunoelectron microscopic evidence for tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathogens 2010, 6:e1000749.
26. Hauser H., Lopez L.A., Yang S.J., Oldenburg J.E., Exline C.M., Guatelli J.C., Cannon P.M. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 2010, 7:51.
27. Hinz A., Miguet N., Natrajan G., Usami Y., Yamanaka H., Renesto P., Hartlieb B., McCarthy A.A., Simorre J.P., Gottlinger H., et al. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host & Microbe 2010, 7:314-323.
28. Ishikawa J., Kaisho T., Tomizawa H., Lee B.O., Kobune Y., Inazawa J., Oritani K., Itoh M., Ochi T., Ishihara K., et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995, 26:527-534.
29. Iwabu Y., Fujita H., Kinomoto M., Kaneko K., Ishizaka Y., Tanaka Y., Sata T., Tokunaga K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. Journal of Biological Chemistry 2009, 284:35060-35072.
30. Jia B., Serra-Moreno R., Neidermyer W., Rahmberg A., Mackey J., Fofana I.B., Johnson W.E., Westmoreland S., Evans D.T. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathogens 2009, 5:e1000429.
31. Jones P.H., Mehta H.V., Maric M., Roller R.J., Okeoma C.M. Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology 2012, 9:10.
32. Jouvenet N., Neil S.J., Zhadina M., Zang T., Kratovac Z., Lee Y., McNatt M., Hatziioannou T., Bieniasz P.D. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. Journal of Virology 2009, 83:1837-1844.
33. Kaletsky R.L., Francica J.R., Agrawal-Gamse C., Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:2886-2891.
34. Kerkmann M., Rothenfusser S., Hornung V., Towarowski A., Wagner M., Sarris A., Giese T., Endres S., Hartmann G. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. Journal of Immunology 2003, 170:4465-4474.
35. Kobayashi T., Ode H., Yoshida T., Sato K., Gee P., Yamamoto S.P., Ebina H., Strebel K., Sato H., Koyanagi Y. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. Journal of Virology 2011, 85:932-945.
36. Kong W.S., Irie T., Yoshida A., Kawabata R., Kadoi T., Sakaguchi T. Inhibition of virus-like particle release of Sendai virus and Nipah virus, but not that of mumps virus, by tetherin/CD317/BST-2. Hiroshima Journal of Medical Sciences 2012, 61:59-67.
37. Kuhl A., Banning C., Marzi A., Votteler J., Steffen I., Bertram S., Glowacka I., Konrad A., Sturzl M., Guo J.T., et al. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. Journal of Infectious Diseases 2011, 204(Suppl. 3):S850-S860.
38. Kumagai Y., Kumar H., Koyama S., Kawai T., Takeuchi O., Akira S. Cutting edge: TLR-dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-{alpha} production in plasmacytoid dendritic cells. Journal of Immunology 2009, 182:3960-3964.
39. Kupzig S., Korolchuk V., Rollason R., Sugden A., Wilde A., Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003, 4:694-709.
40. Laguette N., Benkirane M. How SAMHD1 changes our view of viral restriction. Trends in Immunology 2012, 33:26-33.
41. Le Tortorec A., Neil S.J. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. Journal of Virology 2009, 83:11966-11978.
42. Liberatore R.A., Bieniasz P.D. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:18097-18101.
43. Lim E.S., Emerman M. Simian immunodeficiency virus SIVagm from African green monkeys does not antagonize endogenous levels of African green monkey tetherin/BST-2. Journal of Virology 2009, 83:11673-11681.
44. Liu M.Q., Zhou D.J., Wang X., Zhou W., Ye L., Li J.L., Wang Y.Z., Ho W.Z. IFN-lambda3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS ONE 2012, 7:e35902.
45. Lopez L.A., Yang S.J., Hauser H., Exline C.M., Haworth K.G., Oldenburg J., Cannon P.M. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. Journal of Virology 2010, 84:7243-7255.
46. Loschko J., Schlitzer A., Dudziak D., Drexler I., Sandholzer N., Bourquin C., Reindl W., Krug A.B. Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity. Journal of Immunology 2011, 186:6718-6725.
47. Lukacs-Kornek V., Malhotra D., Fletcher A.L., Acton S.E., Elpek K.G., Tayalia P., Collier A.R., Turley S.J. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nature Immunology 2011, 12:1096-1104.
48. Malhotra D., Fletcher A.L., Astarita J., Lukacs-Kornek V., Tayalia P., Gonzalez S.F., Elpek K.G., Chang S.K., Knoblich K., Hemler M.E., et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature Immunology 2012, 13:499-510.
49. Mangeat B., Cavagliotti L., Lehmann M., Gers-Huber G., Kaur I., Thomas Y., Kaiser L., Piguet V. Influenza virus partially counteracts restriction imposed by tetherin/BST-2. Journal of Biological Chemistry 2012, 287:22015-22029.
50. Mansouri M., Viswanathan K., Douglas J.L., Hines J., Gustin J., Moses A.V., Fruh K. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. Journal of Virology 2009, 83:9672-9681.
51. Masuyama N., Kuronita T., Tanaka R., Muto T., Hirota Y., Takigawa A., Fujita H., Aso Y., Amano J., Tanaka Y. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. Journal of Biological Chemistry 2009, 284:15927-15941.
52. McNatt M.W., Zang T., Hatziioannou T., Bartlett M., Fofana I.B., Johnson W.E., Neil S.J., Bieniasz P.D. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathogens 2009, 5:e1000300.
53. Mitchell R.S., Katsura C., Skasko M.A., Fitzpatrick K., Lau D., Ruiz A., Stephens E.B., Margottin-Goguet F., Benarous R., Guatelli J.C. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathogens 2009, 5:e1000450.
54. Moore R.C., Lee I.Y., Silverman G.L., Harrison P.M., Strome R., Heinrich C., Karunaratne A., Pasternak S.H., Chishti M.A., Liang Y., et al. Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. Journal of Molecular Biology 1999, 292:797-817.
55. Mueller S.N., Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nature Reviews Immunology 2009, 9:618-629.
56. Nakayama E.E., Shioda T. Anti-retroviral activity of TRIM5 alpha. Reviews in Medical Virology 2010, 20:77-92.
57. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
58. Ohtomo T., Sugamata Y., Ozaki Y., Ono K., Yoshimura Y., Kawai S., Koishihara Y., Ozaki S., Kosaka M., Hirano T., et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochemical and Biophysical Research Communications 1999, 258:583-591.
59. Pardieu C., Vigan R., Wilson S.J., Calvi A., Zang T., Bieniasz P., Kellam P., Towers G.J., Neil S.J. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathogens 2010, 6:e1000843.
60. Perez-Caballero D., Zang T., Ebrahimi A., McNatt M.W., Gregory D.A., Johnson M.C., Bieniasz P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139:499-511.
61. Radoshitzky S.R., Dong L., Chi X., Clester J.C., Retterer C., Spurgers K., Kuhn J.H., Sandwick S., Ruthel G., Kota K., et al. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. Journal of Virology 2010, 84:10569-10580.
62. Randall T.D. Stromal cells put the brakes on T-cell responses. Immunology and Cell Biology 2012, 90:469-470.
63. Rolink A.G., Schaniel C., Busslinger M., Nutt S.L., Melchers F. Fidelity and infidelity in commitment to B-lymphocyte lineage development. Immunological Reviews 2000, 175:104-111.
64. Rollason R., Korolchuk V., Hamilton C., Schu P., Banting G. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. Journal of Cell Science 2007, 120:3850-3858.
65. Sakuma T., Noda T., Urata S., Kawaoka Y., Yasuda J. Inhibition of Lassa and Marburg virus production by tetherin. Journal of Virology 2009, 83:2382-2385.
66. Sauter D., Schindler M., Specht A., Landford W.N., Munch J., Kim K.A., Votteler J., Schubert U., Bibollet-Ruche F., Keele B.F., et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host & Microbe 2009, 6:409-421.
67. Sauter D., Specht A., Kirchhoff F. Tetherin: holding on and letting go. Cell 2010, 141:392-398.
68. Schliemann C., Roesli C., Kamada H., Borgia B., Fugmann T., Klapper W., Neri D. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood 2010, 115:736-744.
69. Schubert H.L., Zhai Q., Sandrin V., Eckert D.M., Garcia-Maya M., Saul L., Sundquist W.I., Steiner R.A., Hill C.P. Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:17951-17956.
70. Seo J.Y., Yaneva R., Cresswell P. Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host & Microbe 2011, 10:534-539.
71. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
72. Silveira N.J., Varuzza L., Machado-Lima A., Lauretto M.S., Pinheiro D.G., Rodrigues R.V., Severino P., Nobrega F.G., Silva W.A., de B Pereira C.A., et al. Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Medical Genomics 2008, 1:56.
73. Skaug B., Chen Z.J. Emerging role of ISG15 in antiviral immunity. Cell 2010, 143:187-190.
74. Swiecki M., Scheaffer S.M., Allaire M., Fremont D.H., Colonna M., Brett T.J. Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. Journal of Biological Chemistry 2011, 286:2987-2997.
75. Swiecki M., Wang Y., Gilfillan S., Lenschow D.J., Colonna M. Cutting edge: paradoxical roles of BST2/tetherin in promoting type I IFN response and viral infection. Journal of Immunology 2012, 188:2488-2492.
76. Tai Y.T., Horton H.M., Kong S.Y., Pong E., Chen H., Cemerski S., Bernett M.J., Nguyen D.H., Karki S., Chu S.Y., et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 2012, 119:2074-2082.
77. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host & Microbe 2008, 3:245-252.
78. Vigan R., Neil S.J. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. Journal of Virology 2010, 84:12958-12970.
79. Viswanathan K., Smith M.S., Malouli D., Mansouri M., Nelson J.A., Fruh K. BST2/tetherin enhances entry of human cytomegalovirus. PLoS Pathogens 2011, 7:e1002332.
80. Wainwright D.A., Balyasnikova I.V., Han Y., Lesniak M.S. The expression of BST2 in human and experimental mouse brain tumors. Experimental and Molecular Pathology 2011, 91:440-446.
81. Wang W., Nishioka Y., Ozaki S., Jalili A., Abe S., Kakiuchi S., Kishuku M., Minakuchi K., Matsumoto T., Sone S. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunology, Immunotherapy 2009, 58:967-976.
82. Watanabe R., Leser G.P., Lamb R.A. Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology 2011, 417:50-56.
83. Weidner J.M., Jiang D., Pan X.B., Chang J., Block T.M., Guo J.T. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. Journal of Virology 2010, 84:12646-12657.
84. Xu F., Tan J., Liu R., Xu D., Li Y., Geng Y., Liang C., Qiao W. Tetherin inhibits prototypic foamy virus release. Virology Journal 2011, 8:198.
85. Yang H., Wang J., Jia X., McNatt M.W., Zang T., Pan B., Meng W., Wang H.W., Bieniasz P.D., Xiong Y. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:18428-18432.
86. Yokoyama T., Enomoto T., Serada S., Morimoto A., Matsuzaki S., Ueda Y., Yoshino K., Fujita M., Kyo S., Iwahori K., et al. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. International Journal of Cancer 2013, 132:472-484.
87. Yondola M.A., Fernandes F., Belicha-Villanueva A., Uccelini M., Gao Q., Carter C., Palese P. Budding capability of the influenza virus neuraminidase can be modulated by tetherin. Journal of Virology 2011, 85:2480-2491.
88. Yoo H., Park S.H., Ye S.K., Kim M. IFN-gamma-induced BST2 mediates monocyte adhesion to human endothelial cells. Cellular Immunology 2011, 267:23-29.
89. Zhang F., Wilson S.J., Landford W.C., Virgen B., Gregory D., Johnson M.C., Munch J., Kirchhoff F., Bieniasz P.D., Hatziioannou T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host & Microbe 2009, 6:54-67.